The Little Engine that Wouldn’t: Supranational Entrepreneurship and the Barroso Commission

This paper seeks to evaluate and explain the degree of supranational entrepreneurship shown by the European Commission following the global financial crisis. Focusing on the period 2007–2011, it finds that the Commission used its right of initiative and/or mobilised ideas and information to pursue a supranational European Union (EU) economic policy in few cases. These findings are explained with reference to strategic entrepreneurship, that is the Commission’s reluctance to support integrationist initiatives unless they stand a chance of success, and by the fact that partisanship took precedence for the EU executive over the pursuit of integration in some cases. The Commission could yet capitalise on the crisis but its actions in this period call for greater attention by scholars to preference formation by supranational actors as well as a reconsideration of what it means for the EU executive to lead

Effect of topical ketanserin administration on intraocular pressure.

The effect of topical ketanserin on intraocular pressure (IOP) in normotensive and hypertensive eyes was evaluated. The study was performed on 10 healthy volunteers and 10 glaucomatous patients. Systolic arterial blood pressure (SBP), diastolic arterial blood pressure (DBP), heart rate (HR), IOP, tonographic outflow facility, pupil diameter, corneal thickness, and tear secretion were recorded at baseline and at 1 hour intervals for 12 hours after topical administration of 0.5% ketanserin or placebo, given in a randomised, double masked, crossover fashion. The alternative treatment was given 1 week later. In all subjects ketanserin significantly lowered IOP, while no variations in SBP, DBP, HR, pupil diameter, corneal thickness, and tear secretion were found. When subjects received placebo no significant variations of IOP occurred. Total outflow facility, measured by conventional tonography, increased significantly after drug administration in all subjects. Ketanserin is effective up to 6 hours in control subjects and 9 hours in glaucomatous patients. The placebo did not induce any change in this component of the aqueous humour dynamic in normal or in glaucomatous eyes. The findings indicate that topical ketanserin might be added to the list of antiglaucomatous agents